학술논문
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Document Type
Article
Author
Source
In: Oncogene . (Oncogene, 11 November 2022, 41(46):5046-5060)
Subject
Language
English
ISSN
14765594
09509232
09509232